What treatments are available for PNH?
Ravulizumab and eculizumab (trade name: Soliris®), known as complement inhibitors, aim to
prevent the destruction of the red blood cells, improve common symptoms of PNH, and prevent
life-threatening complications.
Complement inhibitors work by sticking to a protein in the blood called C5, which helps stop the red
blood cells from breaking down.
Complement inhibitor Protective protein Less destruction
treatment given directly shields red blood happening to red
into the bloodstream cell from attack blood cell
What were the treatments used in this study?
There were 4 groups in the study. Each group got a different dosing regimen of ravulizumab. This
means that different doses of ravulizumab were given at different times for the 4 groups during the
study. The treatment was given by an infusion, which means it was administered directly into the
bloodstream via a drip.
GROUP 1 GROUP 2 GROUP 3 GROUP 4
1400 mg on Day 1, then 2000 mg on Day 1, then 1600 mg on Day 1 and 3000 mg on Day 1, then
1000 mg on Day 15, 1600 mg on Day 22, Day 15, then 2400 mg on 5400 mg on Day 29
Day 29, and once every Day 43, and once every Day 29 and once every and once every
4 weeks after that 6 weeks after that 8 weeks after that 12 weeks after that
Patients in Groups 1, 2, and 3 had an end of treatment visit on Day 253, which was around 36 weeks
of treatment. Patients in Group 4 had an end of treatment visit on Day 281, which was around
40 weeks of treatment.
Protocol, ALXN1210-PNH-201 SPONSOR CONTACT INFORMATION:
Europe, 2015-002674-20 1-888-765-4747
© Certara USA, Inc. 2020. All rights reserved United States, NCT02605993 medinfo@alexion.com 3